Residency · Residency · Neurosurgery

Cerebral Vasospasm and Delayed Cerebral Ischemia

Overview

Cerebral vasospasm and delayed cerebral ischemia (DCI) are the leading causes of morbidity and mortality following aneurysmal subarachnoid hemorrhage (aSAH) in patients who survive the initial hemorrhage and aneurysm treatment. Angiographic vasospasm occurs in 40-70% of aSAH patients, while symptomatic DCI develops in 20-30%. The critical window is days 4-14 after hemorrhage. Prevention, early detection, and aggressive treatment are essential to minimize ischemic brain injury.

Definitions

Angiographic vasospasm refers to narrowing of cerebral arteries on imaging (DSA, CTA) compared with baseline. Clinical or symptomatic vasospasm denotes a new neurological deficit (confusion, focal deficit, decreased consciousness) attributable to vasospasm after excluding other causes. Delayed cerebral ischemia is the more clinically meaningful endpoint, defined as clinical deterioration or new infarction on imaging attributable to vasospasm and not explained by other causes. Importantly, DCI can occur without detectable angiographic vasospasm through mechanisms including microvascular dysfunction, cortical spreading depolarization, and microthrombosis.

Pathophysiology

Oxyhemoglobin released from lysed red blood cells in the subarachnoid space is the primary trigger for vasospasm. This initiates a cascade of mechanisms: endothelin-1 upregulation (a potent vasoconstrictor), nitric oxide scavenging with reduced NO bioavailability, free radical generation and lipid peroxidation, inflammation with leukocyte infiltration of vessel walls, and structural remodeling of the arterial wall through smooth muscle hyperplasia and fibrosis. Cortical spreading depolarization consists of waves of neuronal depolarization that may cause vasoconstriction and ischemia. Microthrombosis from platelet activation and microvascular thrombosis occurs independently of large-vessel spasm. Disrupted autoregulation makes the brain vulnerable to hypotension.

Risk Factors for Vasospasm/DCI

The volume of subarachnoid blood (Modified Fisher grade 3-4) is the strongest predictor. Other risk factors include Hunt and Hess grade III-V, young age (more robust arterial reactivity), cigarette smoking, cocaine use, hypovolemia, hyponatremia, previous history of vasospasm, and longer duration between hemorrhage and aneurysm treatment.

Monitoring and Detection

Clinical Assessment

Frequent neurological examinations every 1-2 hours during the risk window form the foundation of monitoring. Decline in GCS, new focal deficit, confusion, or agitation should raise suspicion for DCI. The major limitation is unreliability in sedated, intubated, or poor-grade patients.

Transcranial Doppler (TCD) Ultrasonography

TCD is a non-invasive, bedside, repeatable modality that measures mean flow velocity in major cerebral arteries, with the MCA most commonly monitored. The Lindegaard ratio (MCA mean flow velocity divided by extracranial ICA mean flow velocity) helps distinguish vasospasm from hyperemia: a ratio greater than 3 suggests vasospasm, while a ratio greater than 6 indicates severe vasospasm. MCA mean flow velocity thresholds are: below 120 cm/s for normal or mild spasm, 120-200 cm/s for moderate vasospasm, and above 200 cm/s for severe vasospasm. Daily TCD monitoring runs from days 3-14. Limitations include operator dependence, poor acoustic windows in 10-15% of patients, and inability to detect distal vessel spasm.

CT Angiography (CTA)

CTA rapidly identifies large-vessel vasospasm with a sensitivity of approximately 85-90% compared with DSA. It can be combined with CT perfusion to assess tissue at risk.

CT Perfusion

CT perfusion identifies regions of reduced cerebral blood flow before infarction occurs. Prolonged mean transit time and reduced cerebral blood flow suggest tissue at risk. These findings may guide decisions regarding endovascular intervention.

Digital Subtraction Angiography (DSA)

DSA remains the gold standard for vasospasm diagnosis and is both diagnostic and therapeutic, allowing immediate endovascular treatment. It is reserved for patients with clinical suspicion of DCI or positive non-invasive screening.

Multimodality Monitoring (Advanced)

Advanced monitoring options include continuous EEG (where alpha-delta ratio changes may detect early ischemia), brain tissue oxygen (PbtO2) monitoring, cerebral microdialysis (where elevated lactate/pyruvate ratio indicates metabolic crisis), and invasive ICP monitoring with EVD.

<image> Digital subtraction angiography (DSA) comparison showing a normal caliber middle cerebral artery and anterior cerebral artery on post-SAH day 1 (baseline) versus severe vasospasm on day 7 with marked narrowing of the M1 segment and A1 segment. An adjacent panel shows the post-treatment angiogram after intra-arterial verapamil and balloon angioplasty demonstrating improved vessel caliber. Transcranial Doppler velocity tracings are shown with corresponding MFV values for normal, moderate, and severe vasospasm. Radiological and neurophysiological teaching illustration. </image>

Prevention

Nimodipine

Oral nimodipine 60 mg every 4 hours for 21 days is the only proven pharmacologic intervention that improves outcomes. It does not significantly reduce angiographic vasospasm; its mechanism is likely neuroprotective. If hypotension occurs, the dose should be reduced to 30 mg every 2 hours rather than discontinuing. Intravenous nimodipine is available in some countries but not in the US or Canada.

Euvolemic Fluid Management

Euvolemia is maintained with isotonic crystalloid (0.9% normal saline). Hypovolemia must be avoided as it worsens DCI. Prophylactic hypervolemia (formerly part of "triple-H therapy") is not beneficial and increases complications including pulmonary edema and dilutional hyponatremia. Volume status is monitored with central venous pressure, fluid balance, or advanced hemodynamic monitoring.

Statins, Magnesium, and Clazosentan

Statins have mixed evidence with some studies suggesting reduction in DCI, but they are currently not standard of care. The MASH-2 trial showed no benefit for routine magnesium supplementation. Clazosentan (an endothelin receptor antagonist) reduced angiographic vasospasm in the CONSCIOUS trials but did not improve clinical outcomes and is not recommended.

Treatment of Symptomatic Vasospasm/DCI

Medical (First-Line)

Hemodynamic augmentation with induced hypertension is the cornerstone of medical treatment. Target systolic blood pressure of 180-220 mmHg (in patients with secured aneurysms) is achieved using vasopressors such as norepinephrine or phenylephrine. The former "triple-H therapy" (hypertension, hypervolemia, hemodilution) has been simplified to induced hypertension alone, as hypervolemia and hemodilution are not individually beneficial. Blood pressure is elevated in a stepwise fashion with clinical response assessment after each increment. If neurological improvement occurs, the effective target is maintained.

Additional medical measures include euvolemia maintenance with aggressive isotonic fluid administration, optimizing hemoglobin (transfusing if hemoglobin falls below 8-9 g/dL, though some advocate higher thresholds during active DCI), and avoiding fever since it worsens ischemic injury.

Endovascular (Second-Line)

Endovascular treatment is indicated for medically refractory DCI when no improvement occurs with maximal hemodynamic augmentation.

Intra-arterial vasodilators include verapamil (most commonly used, at 10-20 mg per vessel), nicardipine (an alternative calcium channel blocker), and milrinone (a phosphodiesterase inhibitor used at some centers intra-arterially or intravenously). The effect is often transient, lasting hours to days, and may require repeated treatments. Vasodilators can be delivered selectively to affected territories.

Balloon angioplasty provides mechanical dilation of spastic proximal vessels (ICA, M1, A1, basilar). It offers a more durable effect than pharmacologic vasodilation but carries risks of vessel rupture (1-5%), dissection, and reperfusion hemorrhage. It cannot be performed on distal vessels that are too small and fragile. Treatment is most effective when performed early after symptom onset.

Rescue Therapies

Rescue options for refractory cases include intra-arterial milrinone infusion, lumbar drainage of bloody CSF to remove spasmogenic blood products, intrathecal vasodilators (nicardipine pellets, intrathecal milrinone) which remain experimental, and high-dose intra-arterial nicardipine continuous infusion via an indwelling catheter.

Cerebral Infarction from DCI

Despite optimal management, 15-20% of aSAH patients develop DCI-related infarction. This represents the strongest predictor of poor long-term functional outcome after aSAH, apart from the initial hemorrhage severity. The infarction distribution may be in territories remote from the ruptured aneurysm due to global vasospasm. Follow-up imaging (CT or MRI) is essential to document the extent of infarction.

<image> Flowchart for the management of suspected delayed cerebral ischemia after SAH. Starting with clinical deterioration during the vasospasm window (days 4-14), the algorithm includes initial assessment (exclude re-hemorrhage, hydrocephalus, seizure, metabolic causes with urgent CT), followed by medical management (hemodynamic augmentation with induced hypertension, euvolemia, nimodipine continuation), monitoring with TCD and CTA/CTP, and escalation to endovascular therapy (intra-arterial vasodilators, balloon angioplasty) if refractory. Response assessment at each step guides further management. Clean clinical algorithm with decision points. </image>

Clinical Pearls

DCI is a clinical diagnosis; not all patients with angiographic vasospasm develop DCI, and DCI can occur without visible large-vessel vasospasm due to microvascular dysfunction and cortical spreading depolarization. Nimodipine is the only proven pharmacologic intervention that improves outcomes and must be given for the full 21 days regardless of vasospasm status. Induced hypertension (not hypervolemia) is the effective hemodynamic intervention; prophylactic hypervolemia increases pulmonary complications without benefit and has been abandoned. TCD is useful for trending but has significant limitations: a normal TCD does not exclude DCI, and elevated velocities may reflect hyperemia rather than vasospasm (the Lindegaard ratio helps distinguish these). CT perfusion provides the best non-invasive assessment of tissue at risk and can guide the decision for endovascular intervention. Balloon angioplasty is more durable than intra-arterial vasodilators for proximal vessel spasm but carries a small risk of vessel rupture and cannot treat distal vasospasm. Hyponatremia during the vasospasm window must be managed with volume replacement (cerebral salt wasting), not fluid restriction, as fluid restriction is dangerous in SAH patients and will worsen DCI.

References

• Vergouwen MD, et al. "Definition of Delayed Cerebral Ischemia after Aneurysmal Subarachnoid Hemorrhage as an Outcome Event in Clinical Trials and Observational Studies." Stroke. 2010;41(10):2391-2395.
• Diringer MN, et al. "Critical Care Management of Patients Following Aneurysmal Subarachnoid Hemorrhage." Stroke. 2011;42(6):1707-1730.
• Pickard JD, et al. "Effect of Oral Nimodipine on Cerebral Infarction and Outcome after Subarachnoid Haemorrhage." BMJ. 1989;298(6674):636-642.
• Frontera JA, et al. "Prediction of Symptomatic Vasospasm after Subarachnoid Hemorrhage: The Modified Fisher Scale." Neurosurgery. 2006;59(1):21-27.
• Connolly ES Jr, et al. "Guidelines for the Management of Aneurysmal Subarachnoid Hemorrhage." Stroke. 2012;43(6):1711-1737.

Read this lecture as Markdown